Jacqueline E. Shea - 10 May 2025 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)

Signature
/s/ Jacqueline E. Shea
Issuer symbol
INO
Transactions as of
10 May 2025
Net transactions value
-$4,306
Form type
4
Filing time
12 May 2025, 16:39:38 UTC
Previous filing
28 Feb 2025
Next filing
16 May 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Shea Jacqueline Elizabeth Chief Executive Officer, Director 660 W. GERMANTOWN PIKE, PLYMOUTH MEETING /s/ Jacqueline E. Shea 12 May 2025 0001771498

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INO Common Stock Options Exercise +5,500 +12% 52,050 10 May 2025 Direct F1
transaction INO Common Stock Tax liability $4,306 -2,392 -4.6% $1.80 49,658 10 May 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INO Restricted Stock Unit Options Exercise $0 -5,500 -100% $0.000000 0 10 May 2025 Common Stock 5,500 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 16,500 restricted stock units was as follows: 5,500 shares vested on May 10, 2023; 5,500 shares vested on May 10, 2024; and 5,500 shares vested on May 10, 2025. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both.
F2 The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.